Company Overview
Snapshot
Founded in June 2013 by Yossi Yamin and Martin Aebi, SpacePharma operates with 11–50 employees. The company has raised a total of $19.98 million across four funding rounds from State of Mind Ventures. In March 2024, SpacePharma secured a grant from the European Innovation Council.
Business overview
SpacePharma specializes in leveraging microgravity for research and development, particularly within the pharmaceutical and biotechnology sectors. The company develops end-to-end miniaturized lab systems, such as mGnify, equipped with sensors and readers capable of operating on various microgravity platforms, including its own nanosatellites. SpacePharma supports clients through all stages of microgravity experiments, from planning and preparation to execution and analysis, serving industries focused on drug discovery, protein crystallization, and tissue development.
Strategic signal
In January 2026, SpacePharma R&D Israel Ltd was selected by the EIC Accelerator blended phase to build SPACTORY, the first in-orbit monoclonal antibodies factory outside the atmosphere. This selection from 968 proposals validates SpacePharma's leadership in space-based biomanufacturing and signals a significant advancement in leveraging microgravity for pharmaceutical production, potentially accelerating drug development and manufacturing capabilities beyond Earth.
Log in to access full profile ›Company Intelligence Q&A
- What is SpacePharma's core focus?
- SpacePharma focuses on utilizing microgravity for research and development, offering miniaturized, remotely-controlled lab systems for experiments in space, particularly for drug discovery and medical advancements.
- When was SpacePharma founded and by whom?
- SpacePharma was founded in June 2013 by co-founders Yossi Yamin and Martin Aebi.
- What significant grant did SpacePharma receive in March 2024?
- In March 2024, SpacePharma received a grant from the European Innovation Council.
- What is the SPACTORY project?
- In January 2026, SpacePharma R&D Israel Ltd was selected by the European Innovation Council Accelerator program to build the SPACTORY, which will be the first in-orbit monoclonal antibodies factory outside the atmosphere.
- What was the nature of the collaboration between BSGN, SpacePharma, and Roche?
- In December 2024, BSGN (Business in Space Growth Network), SpacePharma, and Roche collaborated on SPANCER, a project utilizing SpacePharma's microgravity labs to create consistent, high-quality 3D human tissues for cancer diagnostics and treatments, supported by ESA's BSGN accelerator program.